Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxUPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxUPDATE: Phase 1b Data for ORIC-944 in Combination with AR Inhibitors in mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1/2 Clinical Trial: 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1 Study Results of JNJ-78278343 (pasritamig) in mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: 177Lu-NYM032 Shows Efficacy In mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPRESERVE-006 Phase 1 Trial Results: Gotistobart (BNT316/ONC-392) and 177Lu Combination Shows Promise for mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxVIOLET Phase 1/2 Trial Final Results: 161Tb-PSMA-I&T Shows Promising Results
/0 Comments/in Metastatic, Phase 1, Phase 2/by MaxPhase 1/2 Trial of Novel Radioligand Therapy 177Lu-JH020002 Shows Promise
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy cancer treatment castration-resistant prostate cancer CDK12 clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology olaparib oncolytic virus personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- (no title) June 11, 2025
- Newsletter 23/2025 June 8, 2025
- Protein Design Leaps Forward Thanks to AI June 5, 2025
- Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors June 5, 2025